(Reuters) - Cigna said on Monday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement in 2025, and recommend less pricey ...
The biosimilar price is about 85% lower than that of branded Humira. More than 100,000 Accredo patients use either Humira or one of its biosimilars. 9 Out of the Last 10 Summers this "Power Pattern" ...
The FINANCIAL — Sandoz, a Novartis division and one of the global leaders in biosimilars, announced a global resolution of all intellectual property related litigation with AbbVie concerning the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results